ATXI

Avenue Therapeutics, Inc. (NASDAQ:ATXI) is a specialty pharmaceutical company founded in 2015 and headquartered in New York, New York. The company went public in June 2017 and focuses on developing and commercializing pharmaceutical products specifically designed for use in acute and intensive care hospital settings. Avenue Therapeutics operates as a clinical-stage biotechnology company with its primary asset being an intravenous formulation of Tramadol currently in Phase III clinical trials.